Evidence map›Paper›PMID 41533848›Full record

ArticleTranslational vision science & technology2026

Whole-Genome Landscape of Retinal Hemangioblastomas.

Kiki Bals, Anass Hajjaj, Koen A van Overdam, Marc Veckeneer, Bianca M de Graaf, Bert Eussen, Tom Brands, Rogier A Oldenburg, Maria M Alves, Robert M Verdijk and 4 more

Abstract read
In one paragraph

Article in Translational vision science & technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Kiki BalsDepartment of Ophthalmology, Erasmus MC, CA Rotterdam, The Netherlands.
Anass HajjajDepartment of Ophthalmology, Erasmus MC, CA Rotterdam, The Netherlands.
Koen A van OverdamErasmus MC Cancer Institute, CA Rotterdam, The Netherlands.
Marc VeckeneerDepartment of Ophthalmology, ZAS Cadix, Antwerpen, Belgium.
Bianca M de GraafDepartment of Clinical Genetics, Erasmus MC, CA Rotterdam, The Netherlands.
Bert EussenDepartment of Clinical Genetics, Erasmus MC, CA Rotterdam, The Netherlands.
Tom BrandsDepartment of Clinical Genetics, Erasmus MC, CA Rotterdam, The Netherlands.
Rogier A OldenburgDepartment of Clinical Genetics, Erasmus MC, CA Rotterdam, The Netherlands.
Maria M AlvesDepartment of Clinical Genetics, Erasmus MC, CA Rotterdam, The Netherlands.
Robert M VerdijkErasmus MC Cancer Institute, CA Rotterdam, The Netherlands.
Annelies de KleinDepartment of Clinical Genetics, Erasmus MC, CA Rotterdam, The Netherlands.
Emine KiliçDepartment of Ophthalmology, Erasmus MC, CA Rotterdam, The Netherlands.
Erwin BrosensDepartment of Clinical Genetics, Erasmus MC, CA Rotterdam, The Netherlands.
Rotterdam Ocular Melanoma Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Retinal hemangioblastomas (RHs) are rare benign vascular tumors that present mostly as manifestations of Von Hippel-Lindau (VHL) syndrome. In contrast to other VHL syndrome-associated tumors, only a handful of molecular studies have been published on RHs. It remains unclear whether VHL alterations alone drive RH tumorigenesis. Methods: Whole-genome sequencing (WGS) was performed on germline- and RHs-derived DNA of five patients. Additionally, transcriptomes of four unaffected retinas and five choroid controls were compared with those of RH biopsies. Results: Heterozygous germline missense variants and copy number losses impacting VHL were identified. In all RH biopsies, mosaic loss of chromosome 3 was present, indicating the "second hit" in RHs is likely loss of the complete wild-type chromosome 3. Few additional somatic short nucleotide variants (SNVs) indels, or structural variants with deleterious potential were detected, suggesting that somatic changes are rare but not limited to the VHL gene region. RNA sequencing revealed reduced VHL expression in tumor tissue and downstream gene expression changes consistent with loss of VHL expression. Conclusions: RHs have few somatic changes. Loss of chromosome 3 is likely the second hit in RHs with germline VHL alterations. Translational Relevance: RHs are benign neoplasms with little somatic changes compared with other VHL-syndrome associated tumors. Variants affecting VHL impact downstream gene expression, variants impacting different VHL domains result in differential gene expression of these downstream targets. RNA sequencing may aid in the evaluation of variants of unknown significance.

Indexed as

HemangioblastomaRetinal NeoplasmsAdultChromosomes, Human, Pair 3DNA Copy Number VariationsFemaleGerm-Line MutationHumansMaleMiddle Agedvon Hippel-Lindau DiseaseVon Hippel-Lindau Tumor Suppressor ProteinWhole Genome SequencingVHL protein, humanVon Hippel-Lindau Tumor Suppressor Protein

Identifiers

PMID41533848
PMCPMC12786392

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.